SARC024

A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

TYPE OF SARCOMA: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
DRUG: Regorafenib
ACCRUAL STATUS: Not recruiting

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Robert Maki, MD, PhD
Professor of Medicine
Abramson Cancer Center
University of Pennsylvania School of Medicine

CLINICALTRIALS.GOV IDENTIFIER: NCT02048371

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

PUBLICATIONS:
Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20. PMID: 32701199; PMCID: PMC7648334.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23. PMID: 31013172; PMCID: PMC7799443.

To learn more about this study view Dr. Maki’s SARC024 presentation at the 2021 SARC Semiannual Meeting:

To learn more about this study or to contact the study research staff: